Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 8/20 | 0.58 |
| ▸ | ESR2 | Q92731 | 8/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | FFAR1 | O14842 | 10/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1343883 | 0.85 | FFAR1 (0.51) | KMT2ACYP2C19FFAR1 | |
| SCHEMBL9556420 | 0.85 | FFAR1 (0.51) | KMT2ACYP2C19FFAR1 | |
| SCHEMBL27862777 | 0.85 | FFAR1 (0.51) | KMT2ACYP2C19FFAR1 | |
| SCHEMBL20408613 | 0.84 | FFAR1 (0.60) | KMT2AMEN1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL18382535 | 0.84 | FFAR1 (0.60) | KMT2AMEN1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL17144644 | 0.84 | FFAR1 (0.44) | ESR1ESR2KMT2AMEN1ALDH1A1 | |
| SCHEMBL6801487 | 0.84 | ESR1 (0.56) | ESR1ESR2KMT2AMEN1ALDH1A1 | |
| SCHEMBL10260682 | 0.84 | FFAR1 (0.62) | KMT2AALDH1A1FFAR1 | |
| SCHEMBL5326314 | 0.84 | FFAR1 (0.60) | KMT2AALDH1A1FFAR1 | |
| SCHEMBL11891939 | 0.81 | ESR1 (0.58) | ESR1ESR2KMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2595952-B1 | AGONISTS OF GPR40 | CONNEXIOS LIFE SCIENCES PVT LTD (IN) | 2020-11-18 | — | — | EP | disclosed |
| EP-2595952-B1 | AGONISTS OF GPR40 | CONNEXIOS LIFE SCIENCES PVT LTD (IN) | 2020-11-18 | — | — | EP | disclosed |
| CN-110003169-A | GPR40 receptor agonist, method for preparing same, and pharmaceutical composition containing same as active ingredient | 株式会社LG化学 | 2019-07-12 | — | — | CN | disclosed |
| US-9278915-B2 | Agonists of GPR40 | CONNEXIOS LIFE SCIENCES PVT LTD (IN) | 2016-03-08 | — | — | US | disclosed |
| US-9278915-B2 | Agonists of GPR40 | CONNEXIOS LIFE SCIENCES PVT LTD (IN) | 2016-03-08 | — | — | US | disclosed |
| US-9278915-B2 | Agonists of GPR40 | CONNEXIOS LIFE SCIENCES PVT LTD (IN) | 2016-03-08 | — | — | US | disclosed |
| US-20130237571-A1 | AGONISTS OF GPR40 | Conexios Life Sciences PVT. LTD. (IN) | 2013-09-12 | — | — | US | disclosed |
| US-20130237571-A1 | AGONISTS OF GPR40 | Conexios Life Sciences PVT. LTD. (IN) | 2013-09-12 | — | — | US | disclosed |
| US-20130237571-A1 | AGONISTS OF GPR40 | Conexios Life Sciences PVT. LTD. (IN) | 2013-09-12 | — | — | US | disclosed |
| EP-2595952-A1 | AGONISTS OF GPR40 | Connexios Life Sciences Pvt. Ltd. (IN) | 2013-05-29 | — | — | EP | disclosed |
| WO-2013057743-A1 | PROCESS FOR THE PREPARATION OF AN ARYL OXIME AND SALTS THEREOF | CONNEXIOS LIFE SCIENCES PVT. LTD (IN) | 2013-04-25 | — | — | WO | disclosed |
| WO-2013057743-A1 | PROCESS FOR THE PREPARATION OF AN ARYL OXIME AND SALTS THEREOF | CONNEXIOS LIFE SCIENCES PVT. LTD (IN) | 2013-04-25 | — | — | WO | disclosed |
| WO-2012011125-A1 | AGONISTS OF GPR40 | CONNEXIOS LIFE SCIENCES PVT. LTD. (IN) | 2012-01-26 | — | — | WO | disclosed |
| WO-2012011125-A1 | AGONISTS OF GPR40 | CONNEXIOS LIFE SCIENCES PVT. LTD. (IN) | 2012-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237571-A1 | AGONISTS OF GPR40 | GPR65, GPR55, GPR68 | ESR1 231/4885ESR2 183/4885KMT2A 3880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.